Trial · NCT01587703
Participant flow399
How many started, completed or left each group, period by period.
21 to 40 of 399
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Part1 QD(Median Exposure of 1.38months) | COMPLETED | Part 1: GSK525762 4 mg QD | 0 | |
| Part1 QD(Median Exposure of 1.38months) | COMPLETED | Part 1: GSK525762 8 mg QD | 0 | |
| Part1 QD(Median Exposure of 1.38months) | COMPLETED | Part 1: GSK525762 16 mg QD | 0 | |
| Part1 QD(Median Exposure of 1.38months) | COMPLETED | Part 1: GSK525762 30 mg QD | 0 | |
| Part1 QD(Median Exposure of 1.38months) | COMPLETED | Part 1: GSK525762 60 mg QD | 1 | |
| Part1 QD(Median Exposure of 1.38months) | COMPLETED | Part 1: GSK525762 80 mg QD | 0 | |
| Part1 QD(Median Exposure of 1.38months) | COMPLETED | Part 1: GSK525762 100 mg QD | 0 | |
| Part1 QD(Median Exposure of 1.38months) | COMPLETED | Part 1: GSK525762 20 mg BID | 0 | |
| Part1 QD(Median Exposure of 1.38months) | COMPLETED | Part 1: GSK525762 30 mg BID | 0 | |
| Part1 QD(Median Exposure of 1.38months) | COMPLETED | Part 1: GSK525762 40 mg BID | 0 | |
| Part1 QD(Median Exposure of 1.38months) | COMPLETED | Part 2: Participants With NMC | 0 | |
| Part1 QD(Median Exposure of 1.38months) | COMPLETED | Part 2: Participants With SCLC | 0 | |
| Part1 QD(Median Exposure of 1.38months) | COMPLETED | Part 2: Participants With CRPC | 0 | |
| Part1 QD(Median Exposure of 1.38months) | COMPLETED | Part 2: Participants With TNBC | 0 | |
| Part1 QD(Median Exposure of 1.38months) | COMPLETED | Part 2: Participants With ER+BC | 0 | |
| Part1 QD(Median Exposure of 1.38months) | COMPLETED | Part 2: Participants With GIST | 0 | |
| Part1 QD(Median Exposure of 1.38months) | COMPLETED | 80mg Amor+6mg Iso/80mg Bes+6mg Iso/30mg Bes+6mg Iso/80mg Bes | 0 | |
| Part1 QD(Median Exposure of 1.38months) | COMPLETED | 80mg Bes+6mg Iso/80mg Amor+6mg Iso/30mg Bes+6mg Iso/80mg Bes | 0 | |
| Part1 QD(Median Exposure of 1.38months) | NOT COMPLETED | Part 1: GSK525762 2 mg QD | 3 | |
| Part1 QD(Median Exposure of 1.38months) | NOT COMPLETED | Part 1: GSK525762 4 mg QD | 4 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01587703/flow?page=2